These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 8498825)
21. Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials. Moraal B; van den Elskamp IJ; Knol DL; Uitdehaag BM; Geurts JJ; Vrenken H; Pouwels PJ; van Schijndel RA; Meier DS; Guttmann CR; Barkhof F Ann Neurol; 2010 May; 67(5):667-75. PubMed ID: 20437564 [TBL] [Abstract][Full Text] [Related]
22. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504 [TBL] [Abstract][Full Text] [Related]
23. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials? Bonzano L; Roccatagliata L; Mancardi GL; Sormani MP Mult Scler; 2009 Sep; 15(9):1043-7. PubMed ID: 19570818 [TBL] [Abstract][Full Text] [Related]
24. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Calabresi PA; Tranquill LR; Dambrosia JM; Stone LA; Maloni H; Bash CN; Frank JA; McFarland HF Ann Neurol; 1997 May; 41(5):669-74. PubMed ID: 9153530 [TBL] [Abstract][Full Text] [Related]
25. [Leptomeningeal abnormality on Gd-DTPA enhanced MRI in a case of SLE presenting diffuse organic brain syndrome]. Okano R; Kuroki M; Otsuka M; Yamada A; Ueki A Rinsho Shinkeigaku; 1993 Jan; 33(1):78-82. PubMed ID: 8334780 [TBL] [Abstract][Full Text] [Related]
26. Defining interferon beta response status in multiple sclerosis patients. Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896 [TBL] [Abstract][Full Text] [Related]
28. [Serial magnetic resonance imaging of acute disseminated encephalomyelitis, including evaluation of the contrast-enhancing effect of lesions by Gd-DTPA]. Tanaka Y; Matsuo M Nihon Igaku Hoshasen Gakkai Zasshi; 1996 Jan; 56(1):25-31. PubMed ID: 8857095 [TBL] [Abstract][Full Text] [Related]
29. Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months. Koopmans RA; Li DK; Oger JJ; Kastrukoff LF; Jardine C; Costley L; Hall S; Grochowski EW; Paty DW Ann Neurol; 1989 Aug; 26(2):248-56. PubMed ID: 2774512 [TBL] [Abstract][Full Text] [Related]
30. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Barkhof F; Frequin ST; Hommes OR; Lamers K; Scheltens P; van Geel WJ; Valk J Neurology; 1992 Jan; 42(1):63-7. PubMed ID: 1370864 [TBL] [Abstract][Full Text] [Related]
31. Brain metastasis of small cell lung carcinoma: comparison of Gd-DTPA enhanced magnetic resonance imaging and enhanced computerized tomography. Nomoto Y; Miyamoto T; Yamaguchi Y Jpn J Clin Oncol; 1994 Oct; 24(5):258-62. PubMed ID: 7967105 [TBL] [Abstract][Full Text] [Related]
32. [Study of synovial lesions by MRI using gadolinium-DTPA (Gd-DTPA) in patient with early phase of rheumatoid arthritis]. Takano K Ryumachi; 1993 Feb; 33(1):3-11. PubMed ID: 8493583 [TBL] [Abstract][Full Text] [Related]
33. The evolution of the concentric lesions of atypical multiple sclerosis on MRI. Morioka C; Komatsu Y; Tsujio T; Araki Y; Kondo H Radiat Med; 1994; 12(3):129-33. PubMed ID: 7972897 [TBL] [Abstract][Full Text] [Related]
34. [Clinical presentations and MRI findings of angiographically occult vascular malformations]. Kida Y; Kobayashi T; Tanaka T; Oyama H; Iwakoshi T No Shinkei Geka; 1994 Feb; 22(2):141-5. PubMed ID: 8115008 [TBL] [Abstract][Full Text] [Related]
35. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Bastianello S; Pozzilli C; Bernardi S; Bozzao L; Fantozzi LM; Buttinelli C; Fieschi C Neurology; 1990 Apr; 40(4):591-5. PubMed ID: 2320230 [TBL] [Abstract][Full Text] [Related]
36. [Intracranial tumor-like lesions in children and young adults with multiple sclerosis]. Einig M; Higer HP; Mauz M; Ernst JP Rofo; 1992 Oct; 157(4):384-9. PubMed ID: 1391842 [TBL] [Abstract][Full Text] [Related]
37. Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings. Trojano M; Avolio C; Simone IL; Defazio G; Manzari C; De Robertis F; Calò A; Livrea P Neurology; 1996 Dec; 47(6):1535-41. PubMed ID: 8960741 [TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging of intratemporal facial nerve lesions in the animal model. Orloff LA; Duckert LG Laryngoscope; 1995 May; 105(5 Pt 1):465-71. PubMed ID: 7760658 [TBL] [Abstract][Full Text] [Related]
39. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Frank JA; Stone LA; Smith ME; Albert PS; Maloni H; McFarland HF Ann Neurol; 1994; 36 Suppl():S86-90. PubMed ID: 8017894 [TBL] [Abstract][Full Text] [Related]
40. Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. Wiebe S; Lee DH; Karlik SJ; Hopkins M; Vandervoort MK; Wong CJ; Hewitt L; Rice GP; Ebers GC; Noseworthy JH Ann Neurol; 1992 Nov; 32(5):643-50. PubMed ID: 1449244 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]